Home Cart Sign in  
Chemical Structure| 1044589-82-3 Chemical Structure| 1044589-82-3

Structure of NITD008
CAS No.: 1044589-82-3

Chemical Structure| 1044589-82-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NITD008 is a potent and selective flaviviruses inhibitor which can inhibit DENV-2 with an EC50 of 0.64 μM.

Synonyms: 7-Deaza-2'-C-acetylene-adenosine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NITD008

CAS No. :1044589-82-3
Formula : C13H14N4O4
M.W : 290.27
SMILES Code : O[C@@]1(C#C)[C@H](N2C=CC3=C(N)N=CN=C32)O[C@H](CO)[C@H]1O
Synonyms :
7-Deaza-2'-C-acetylene-adenosine
MDL No. :MFCD27952796

Safety of NITD008

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of NITD008

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CRFK cells 0.94 µM 24 hours Evaluate the antiviral effect of NITD008 on FCV, results showed NITD008 significantly inhibited FCV replication Viruses. 2019 May 30;11(6):496
Vero cells 0.67 µM 48 hours To evaluate the in vitro antiviral activity of NITD008 against EV71, results showed that NITD008 effectively inhibited EV71 replication at a concentration of 0.67 μM. J Virol. 2014 Oct;88(20):11915-23
Huh-7 cells 0.11 µM (EC50) 48 hours Evaluate inhibitory effect of NITD008 on HCV, with EC50 of 0.11 μM. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9
DENV-2 cells 0.64 µM (EC50) 48 hours NITD008 inhibited DENV-2 in a dose-responsive manner, with an EC50 value (the compound concentration required to inhibit 50% of viral titer) of 0.64 μM. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9
Huh7 cells 5 µM 48 hours Used for high-throughput screening of anti-JEV compounds. NITD008 served as a positive control, with a Z' value of 0.83 at 0.3 μM, indicating the system is suitable for screening JEV inhibitors. Antiviral Res. 2020 Oct;182:104884
Huh7 cells 0.21 µM 48 hours Evaluate the antiviral effect of NITD008 on human norovirus replicon, results showed NITD008 significantly inhibited replicon levels Viruses. 2019 May 30;11(6):496
RAW264.7 cells 0.91 µM 48 hours Evaluate the antiviral effect of NITD008 on MNV, results showed NITD008 significantly inhibited MNV replication Viruses. 2019 May 30;11(6):496
Vero cells 241 nM (GZ01/2016), 137 nM (FSS13025/2010) 48 hours Inhibited ZIKV replication with EC50 values of 241 nM and 137 nM Open Forum Infect Dis. 2016 Aug 30;3(4):ofw175
Huh7 cells 0.02 to 2.50 µM 72 hours Evaluation of NITD008 inhibition on HEV genotype 1 replicon, showing EC50 of 0.03 μM, CC50>100 μM, therapeutic index>3,333 Antimicrob Agents Chemother. 2019 May 24;63(6):e00003-19
BHK-21 cells 3 µM 72 hours To evaluate the inhibitory effect of NITD008 on eGFP-JEV reporter virus. Results showed dose-dependent inhibitory effects on both eGFP expression and viral titers, with an EC50 of 0.22 μM. Antiviral Res. 2020 Oct;182:104884

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice WNV infection model Oral gavage 10 and 25 mg/kg Twice daily for days 1 to 6 NITD008 significantly attenuates viremia and prevents neuroinvasion, resulting in complete protection from WNV-associated mortality and morbidity. Antiviral Res. 2015 Oct;122:39-45
AG129 mice DENV-2 infection model Oral gavage 25 mg/kg Twice daily for three consecutive days Assessed the antiviral efficacy of NITD008 in a DENV-infected mouse model, showing a significant 20-fold reduction in viremia J Virol. 2014 Feb;88(3):1740-7
Mice AG129 mice Oral 3, 10, 25, 50 mg/kg Twice daily for 3 days Evaluate efficacy of NITD008 in DENV-infected mouse model, showing dose-dependent reduction in viremia and cytokine levels, and complete prevention of death. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9
AG129 mice EV71 infection model Oral 5 mg/kg Twice daily for 3 consecutive days To evaluate the in vivo efficacy of NITD008 in an EV71-infected mouse model, results showed that NITD008 completely prevented clinical symptoms and death. J Virol. 2014 Oct;88(20):11915-23
A129 mice ZIKV infection model Oral 50 mg/kg Once daily for 5 days Significantly reduced viremia and 50% survival rate Open Forum Infect Dis. 2016 Aug 30;3(4):ofw175

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.45mL

0.69mL

0.34mL

17.23mL

3.45mL

1.72mL

34.45mL

6.89mL

3.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories